KVUE Kenvue Inc

$KVUE $KMB — EUROPEAN UNION APPROVES KIMBERLY-CLARK'S ACQUISITION OF KENVUE CONFIRMED REGULATORY DEVELOPMENT: The European Commission has approved Kimberly-Clark's acquisition of Kenvue, subject to divestiture commitments. KEY DETAILS: • Approval follows an antitrust review. • Kimberly-Clark agreed to divest its feminine hygiene brands throughout the European Economic Area. • Affected brands include Kotex, Camelia, Record and Lidie. MARKET TAKEAWAY: The approval removes an important regulatory obstacle to the transaction. However, this does not mean the acquisition has closed. Investors should monitor remaining closing conditions, the timing of the divestitures and any additional regulatory requirements. For merger-arbitrage investors, regulatory progress can reduce transaction uncertainty without eliminating completion risk.

$KVUE on to the next chapter. I'll def continue to hold at least some of the $KMB shares after conversion. Holding 1400+ KVUE between all accounts.

$KVUE dont bother reading these bs chart posts. KMB closing on this very soon. Even earnings really didnt matter.

$KVUE Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $0.29 up 3.57% YoY • Reported revenue of $3.89B up 3.24% YoY • Kenvue expects fiscal year 2026 pre-tax restructuring expenses and other charges of approximately $250M and annualized pre-tax gross cost savings of approximately $200M upon program completion.

$KVUE closed Friday, a day ahead of its outside date. $LXP went this morning. $CBZ should be done today, and $SUPN / $INDV is waiting on the closing release — four deals off the board inside two trading days.

$KVUE Self Care volume swung pretty hard in Q3, up 3.4%, even though volume across the first nine months is still down 0.5%. Pain Care and Cough and Cold in Asia Pacific drove most of it. Skin Health and Beauty went the other way, volume down 1.7% in Q3 on U.S. distribution losses, while nine month volume is still up 1.1%. Its nine month adjusted operating income rose to 503 million dollars from 378 million dollars a year ago.

$KVUE reported before the open this morning. Adjusted EPS of $0.29 missed the $0.29 analyst estimate by 0.6%, according to Stock Meadow. Revenue was $3.89B versus $3.86B expected.

$KVUE's EU review could expire Tuesday. Phase 1 runs 25 working days, not calendar days, so a Brussels holiday moves your closing date. That's most of why this one is hard to pin down.